ClinicalTrials.gg
Not yet recruitingNCT07643376METABARUpdated Jun 11, 2026

Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management

An observational study in Obesity, Morbid, Bariatric Surgery and Intestinal Permeability, sponsored by Toros University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Toros University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Obesity, Morbid with a site in Turkey — 8 open to participants now, 8 under way, 1 of them phase 3. Obesity, Morbid · Turkey.

Planned enrollment
21st of 32
40 · median 68
Started
2026
with 4 others
Observational
32 of 70
5 open now
Registered
65th of 70
by date

Among the 70 studies in Obesity, Morbid with a site in Turkey, this one is the 21st largest by planned enrollment of the 32 observational ones that give a count, is one of 5 that started in 2026, is one of 32 observational ones, and was the 65th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

8 of the 70 studies in Obesity, Morbid with a site in Turkey are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Obesity, Morbid with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.

Obesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.

In this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:

  • Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels
  • Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels
  • Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)
  • Anthropometric measurements: body weight, height, waist and hip circumference, BMI
  • Nutritional intake: 3-day dietary records

The study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.

Read the detailed description

Obesity is defined by the World Health Organization (WHO) as abnormal or excessive fat accumulation that presents a risk to health. Bariatric surgery, particularly Laparoscopic Sleeve Gastrectomy (LSG), is considered the most effective long-term treatment for morbid obesity.

This prospective observational study will be conducted at Bursa Yıldırım Doruk Hospital with 40 volunteers who have undergone LSG within the last month. Participants will be evaluated at baseline (immediately after surgery) and at 6 months post-surgery.

Assessments include:

  1. Anthropometric Measurements: Body weight, height, waist and hip circumference will be measured. BMI and waist-to-hip ratio will be calculated according to WHO criteria.
  2. Biochemical Parameters: Fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels will be obtained from patient records. Zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels will be analyzed using ELISA method (Biotek TS800) with commercial kits (RelAssay® Diagnostics, Ankara, Turkey) at Ankara Diagen Laboratory. Samples will be stored at -20°C until analysis.
  3. Gastrointestinal Symptom Rating Scale (GSRS): A validated 15-item scale assessing five dimensions: diarrhea, indigestion, constipation, abdominal pain, and reflux. Scores range from 1 (no discomfort) to 7 (very severe discomfort). Turkish validity and reliability was established by Turan and Asti (2011).
  4. Dietary Assessment: 3-day dietary records will be collected and analyzed using the Nutrition Information System (BeBIS) 8.2 software. Results will be evaluated according to the Turkish Dietary Guidelines 2022 (TUBER 2022).

Statistical analyses will be performed using the Statistical Package for the Social Sciences (SPSS) 22.0. Normal distribution will be assessed using Kolmogorov-Smirnov/Shapiro-Wilk tests. Results will be expressed as mean ± standard deviation for continuous variables and frequency/percentage for categorical variables.

03

Conditions studied

  • Obesity, Morbid
  • Bariatric Surgery
  • Intestinal Permeability
  • Gastrointestinal Symptoms
  • Metabolic Syndrome

Keywords

  • Laparoscopic Sleeve Gastrectomy
  • Zonulin
  • Secretory IgA
  • Lipopolysaccharide
  • GSRS
  • Body Weight Management
  • Gut microbiota
  • Postoperative Metabolic Parameters
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with morbid obesity who underwent Laparoscopic Sleeve Gastrectomy (LSG) at Bursa Yıldırım Doruk Hospital General Surgery Clinic within the last month, meeting the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month
  • Aged between 19-50 years
  • ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities
  • Signed form
  • Non-smoker and non-alcohol dependent

Exclusion criteria

Exclusion Criteria:

  • Did not undergo or is not planned to undergo LSG
  • Outside the age range of 19-50 years
  • Did not sign the form
  • \<40 kg/m² or BMI \<35 kg/m² without obesity-related comorbidities
  • Smoker or alcohol dependent
  • Has an inflammatory disease
  • Currently using probiotics, antibiotics, or fiber supplements
  • Has a psychiatric disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • LSG Group

    Adults aged 19-50 years who underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last month at Bursa Yıldırım Doruk Hospital. Participants will be evaluated at baseline and 6 months after surgery for metabolic parameters, intestinal permeability markers, gastrointestinal symptoms, anthropometric measurements, and dietary intake.

    Other: Clinical and Biochemical Assessment

Interventions

  • OtherClinical and Biochemical Assessment

    Participants will undergo two assessment visits: at baseline (within 1 month post-surgery) and at 6-month follow-up. Each visit includes anthropometric measurements (body weight, height, waist and hip circumference, BMI), biochemical blood analysis (fasting glucose, lipid profile, insulin, zonulin, secretory IgA, LPS), gastrointestinal symptom evaluation via GSRS, and 3-day dietary records.

    Also known as: Anthropometric Measurement, Biochemical Blood Analysis, Gastrointestinal Symptom Rating Scale (GSRS), 3-Day Dietary Record, Intestinal Permeability Assessment

06

What researchers measure

Primary outcomes

  1. Change in Fasting Blood Glucose Concentration (mg/dL)

    Change in serum fasting blood glucose levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  2. Change in Total Cholesterol Concentration (mg/dL)

    Change in serum total cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  3. Change in Triglyceride Concentration (mg/dL)

    Change in serum triglyceride levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  4. Change in HDL Cholesterol Concentration (mg/dL)

    Change in serum high-density lipoprotein (HDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  5. Change in LDL Cholesterol Concentration (mg/dL)

    Change in serum low-density lipoprotein (LDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  6. Change in VLDL Cholesterol Concentration (mg/dL)

    Change in serum very low-density lipoprotein (VLDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  7. Change in Fasting Insulin Concentration (µIU/mL)

    Change in serum fasting insulin levels after 12-hour fasting between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  8. Change in Serum Zonulin Concentration (ng/mL)

    Change in serum zonulin levels assessed by ELISA method between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  9. Change in Serum Secretory IgA Concentration (mg/dL)

    Change in serum secretory IgA levels assessed by ELISA method between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  10. Change in Serum LPS Concentration (EU/mL)

    Change in serum lipopolysaccharide (LPS) levels assessed by ELISA method between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  11. Change in Gastrointestinal Symptom Rating Scale (GSRS) Total Score (1-7)

    Change in total score of the Gastrointestinal Symptom Rating Scale (GSRS) between baseline and 6-month follow-up. The scale consists of 15 items across 5 subscales; scores range from 1 to 7, with higher scores indicating more severe gastrointestinal symptoms.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in Body Weight (kg)

    Change in body weight between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  2. Change in Body Mass Index (kg/m²)

    Change in BMI between baseline and 6-month follow-up. Weight and height will be combined to report BMI in kg/m².

    Time frame: Baseline and 6 months

  3. Change in Waist Circumference (cm)

    Change in waist circumference between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  4. Change in Hip Circumference (cm)

    Change in hip circumference between baseline and 6-month follow-up.

    Time frame: Baseline and 6 months

  5. Change in Waist-to-Hip Ratio

    Change in waist-to-hip ratio between baseline and 6-month follow-up. Waist and hip circumference measurements will be combined to calculate the waist-to-hip ratio.

    Time frame: Baseline and 6 months

  6. Change in Daily Energy Intake (kcal/day)

    Change in daily energy intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.

    Time frame: Baseline and 6 months

  7. Change in Daily Protein Intake (g/day)

    Change in daily protein intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.

    Time frame: Baseline and 6 months

  8. Change in Daily Carbohydrate Intake (g/day)

    Change in daily carbohydrate intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.

    Time frame: Baseline and 6 months

  9. Change in Daily Fat Intake (g/day)

    Change in daily fat intake assessed by 3-day dietary intake records between baseline and 6-month follow-up. Data will be analyzed using BeBIS 8.2 software.

    Time frame: Baseline and 6 months

07

Study locations

1 site
  • Bursa Yıldırım Doruk Hospital
    Bursa, Bursa 16310, Turkey (Türkiye)
    • Doğukan DURAK;, Assoc. Prof. · Contactdogukandurak404@hotmail.com · +905327243733
    • Betül GÜLŞEN, Assoc. Prof. · Contactbetul.atalay@toros.edu.tr · +903246253300
    • Doğukan Durak, Assoc. Prof. · Sub investigator
    • Betül GÜLŞEN, Assoc. Prof. · Principal investigator
    • Özlem ÖZPAK AKKUŞ, Assoc. Prof. · Principal investigator
    • Seher ŞEN, Asst. Prof. · Sub investigator
    • Tuğçe Nur Doganay Yıldırım, MSc, RD · Sub investigator
08

References and documents

Publications

  • Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998 Jan;7(1):75-83. doi: 10.1023/a:1008841022998. PubMed 9481153 ↗
  • Debedat J, Clement K, Aron-Wisnewsky J. Gut Microbiota Dysbiosis in Human Obesity: Impact of Bariatric Surgery. Curr Obes Rep. 2019 Sep;8(3):229-242. doi: 10.1007/s13679-019-00351-3. PubMed 31197613 ↗
  • Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014 Jan;89(1):107-14. doi: 10.1016/j.mayocp.2013.10.011. PubMed 24388028 ↗
  • Kalarchian MA, King WC, Devlin MJ, White GE, Marcus MD, Garcia L, Yanovski SZ, Mitchell JE. Surgery-related gastrointestinal symptoms in a prospective study of bariatric surgery patients: 3-year follow-up. Surg Obes Relat Dis. 2017 Sep;13(9):1562-1571. doi: 10.1016/j.soard.2017.03.028. Epub 2017 Apr 4. PubMed 28579205 ↗
  • Poves I, Cabrera M, Maristany C, Coma A, Ballesta-Lopez C. Gastrointestinal quality of life after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2006 Jan;16(1):19-23. doi: 10.1381/096089206775222032. PubMed 16417752 ↗
  • Karlsson J, Taft C, Ryden A, Sjostrom L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007 Aug;31(8):1248-61. doi: 10.1038/sj.ijo.0803573. Epub 2007 Mar 13. PubMed 17356530 ↗
  • Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37. doi: 10.1001/jama.292.14.1724. PubMed 15479938 ↗
  • Turan N, Ast TA, Kaya N. Reliability and Validity of the Turkish Version of the Gastrointestinal Symptom Rating Scale. Gastroenterol Nurs. 2017 Jan/Feb;40(1):47-55. doi: 10.1097/SGA.0000000000000177. PubMed 28134719 ↗
  • Pekcan G, Şanlıer N, Baş M, Acar Tek N, Gökmen Özel H. Türkiye Beslenme Rehberi (TÜBER) 2022. Ankara: Hazar Reklamcılık; 2022.
  • Beslenme Bilgi Sistemleri Paket Programı (BeBIS 8.2). İstanbul: Software NDB; 2015.
  • Merdol TK. Toplu Beslenme Yapılan Kurumlar için Standart Yemek Tarifleri. Hatipoğlu Yayınları; 2003.
  • Rakıcıoğlu N, Tek NA, Ayaz A, Pekcan G. Yemek ve Besin Fotoğraf Kataloğu Ölçü ve Miktarlar. Nadir Kitap; 2012.
  • Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452. PubMed 8594834 ↗
  • Pekcan G. Beslenme durumunun saptanması. Diyet El Kitabı. Ankara: Hatipoğlu Yayınevi; 2013:67-142.
  • Kuyucu A. Bariatrik cerrahi uygulanmış hastaların ameliyat sonrası altı ay ve üzeri sürede vücut ağırlığı kaybının, besin tüketim durumunun ve bazı biyokimyasal bulgularının belirlenmesi. Yüksek Lisans Tezi. Gaziantep: Hasan Kalyoncu Üniversitesi Sağlık Bilimleri Enstitüsü; 2018.
  • Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol. 2013 Jul;25(4):488-795. doi: 10.1097/BOR.0b013e32836208de. PubMed 23656715 ↗
  • Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014 Sep;20(9):509-18. doi: 10.1016/j.molmed.2014.05.002. Epub 2014 Jun 20. PubMed 24956966 ↗
  • Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl). 2012 May;221(1):155-69. doi: 10.1007/s00213-011-2555-2. Epub 2012 Jan 11. PubMed 22234378 ↗
  • Chen JC, Lee WJ, Tsou JJ, Liu TP, Tsai PL. Effect of probiotics on postoperative quality of gastric bypass surgeries: a prospective randomized trial. Surg Obes Relat Dis. 2016 Jan;12(1):57-61. doi: 10.1016/j.soard.2015.07.010. Epub 2015 Jul 18. PubMed 26499352 ↗
  • Neil JA, Roberson DW. Enhancing nursing care by understanding the bariatric patient's journey. AORN J. 2015 Aug;102(2):132-40. doi: 10.1016/j.aorn.2015.05.014. PubMed 26227517 ↗
  • King WC, Chen JY, Belle SH, Courcoulas AP, Dakin GF, Elder KA, Flum DR, Hinojosa MW, Mitchell JE, Pories WJ, Wolfe BM, Yanovski SZ. Change in Pain and Physical Function Following Bariatric Surgery for Severe Obesity. JAMA. 2016 Apr 5;315(13):1362-71. doi: 10.1001/jama.2016.3010. PubMed 27046364 ↗
  • Brethauer SA, Chand B, Schauer PR. Risks and benefits of bariatric surgery: current evidence. Cleve Clin J Med. 2006 Nov;73(11):993-1007. doi: 10.3949/ccjm.73.11.993. PubMed 17128540 ↗
  • Poole NA, Al Atar A, Kuhanendran D, Bidlake L, Fiennes A, McCluskey S, Nussey S, Bano G, Morgan JF. Compliance with surgical after-care following bariatric surgery for morbid obesity: a retrospective study. Obes Surg. 2005 Feb;15(2):261-5. doi: 10.1381/0960892053268499. PubMed 15802071 ↗
  • Usta E, Çavdar İ. Obezite cerrahisinde hemşirelik bakımı. Cumhuriyet Hemşirelik Dergisi 2013;2(2):71-77.
  • Monteforte MJ, Turkelson CM. Bariatric surgery for morbid obesity. Obes Surg. 2000 Oct;10(5):391-401. doi: 10.1381/096089200321594246. PubMed 11054242 ↗
  • Satman İ. Türkiye'de obezite sorunu. Türkiye Klinikleri Gastroenterohepatoloji Dergisi 2016;9(2):1-11.
  • Altunkaynak B, Özbek E. Obezite: Nedenleri ve tedavi seçenekleri. Dicle Tıp Dergisi 2007;34(2):144-149.
  • Afshar S, Kelly SB, Seymour K, Woodcock S, Werner AD, Mathers JC. The Effects of Bariatric Procedures on Bowel Habit. Obes Surg. 2016 Oct;26(10):2348-54. doi: 10.1007/s11695-016-2100-9. PubMed 26894909 ↗
  • Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today. 2015 May;50(3):117-128. doi: 10.1097/NT.0000000000000092. Epub 2015 Apr 7. PubMed 27340299 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to ethical considerations and participant confidentiality. Data will be stored securely and used only for the purposes of this study in accordance with Turkish Personal Data Protection Law (KVKK) and the ethical approval pending from Toros University Faculty of Health Sciences Non-Interventional Clinical Research Ethics Committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2027, 6 months later.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 6 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 11, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07643376
Lead sponsor
Toros University
Responsible party
Betül Gülşen (Assoc. Prof., Toros University) — Principal investigator
First posted
Jun 11, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Betül GÜLŞEN, Assoc. Prof.
Contact
betul.atalay@toros.edu.tr
+903246253300
Özlem ÖZPAK AKKUŞ, Assoc. Prof.
Contact
dytozlemozpak@hotmail.com
+903246253300
Betül GÜLŞEN, Assoc. Prof.
principal investigator · Toros University
Özlem ÖZPAK AKKUŞ, Assoc. Prof.
study chair · Toros University
Doğukan DURAK, Assoc. Prof.
study director · Bursa Yıldırım Doruk Hospital, General Surgery Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion